Respiratory Diseases Vaccines Markets, 2020-2025 by Infection, Type, Age Group, Geography and the Impact of Covid-19 – ResearchAndMarkets.com
The “Global Respiratory Diseases Vaccines Market by Infection, Type, Age Group, Geography and the Impact of Covid-19 (2020-2025)” report has been added to ResearchAndMarkets.com’s offering.
“Global Respiratory Diseases Vaccines Market by Infection, Type, Age Group, Geography and the Impact of Covid-19 (2020-2025)”Tweet this
The market is driven by factors such as the increasing prevalence of respiratory diseases, a growing number of vaccines under trial, etc. While the lack of inadequate delivery infrastructure and limited consumer awareness are some of the restraining factors. Increasing R&D expenditure and the increasing availability of vaccines through various collaborations is creating opportunities for market growth.
Respiratory Disease Vaccine Market: Introduction
Respiratory disease affects the lungs and other parts of the respiratory system. In addition to tobacco smoke, other risk factors include air pollution, occupational chemicals and dust, and frequent lower respiratory infections during childhood.
Chronic respiratory diseases (CRDs) are diseases of the airways and other structures of the lung. Some of the most common is chronic obstructive pulmonary disease (COPD), asthma, occupational lung diseases, and pulmonary hypertension.
Treatments for each chronic respiratory disease vary and the ideal solution is the reduction and avoidance of risk factors. Neither asthma nor chronic obstructive pulmonary disease (COPD) can be cured but treatments can reduce symptoms, prevent escalation, and improve quality of life.
Population protection by vaccination against infections has been one of the major achievements of public health and is of considerable importance in controlling respiratory diseases.
The report offers a comprehensive evaluation of the global respiratory disease vaccine market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry. The report includes in-depth market analysis using Porter’s 5 force model. The impact of Covid-19 on the market is also featured in the report.
Key Topics Covered:
1 Introduction
1.1 Objectives of the study
1.2 Market Definition
1.3 Currency
1.4 Years Considered for the study
1.5 Language
1.6 Key Benefits for Shareholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.3 Market Assessment
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
4 Market Overview
4.1 Introduction
4.2 Global Respiratory Disease Vaccine Market Size, by Geography
5 Market Dynamics
5.1 Drivers
5.2 Restraints
5.3 Opportunities
5.4 Trends
6 Market Analysis
6.1 Porter’s Five Forces Analysis
6.2 Impact of COVID-19
7 Global Respiratory Disease Vaccine Market, By Infection
7.1 Introduction
7.2 Influenza Virus
7.3 Pertussis
7.4 Streptococcus Pneumoniae
7.5 Tuberculosis
8 Global Respiratory Disease Vaccine Market, By Type
8.1 Bacterial Vaccine
8.2 Combination Vaccine
8.3 Viral Vaccine
9 Global Respiratory Disease Vaccine Market, By Age Group
9.1 Adolescent Vaccination
9.2 Adult Vaccination
9.3 Infant Vaccination
10 Americas Respiratory Disease Vaccine Market
10.1 Argentina
10.2 Brazil
10.3 Canada
10.4 Mexico
10.5 United States
11 Europe, Middle East & Africa Respiratory Disease Vaccine Market
11.1 France
11.2 Germany
11.3 Italy
11.4 Netherlands
11.5 Qatar
11.6 Russia
11.7 Saudi Arabia
11.8 South Africa
11.9 Spain
11.10 United Arab Emirates
11.11 United Kingdom
12 Asia-Pacific Respiratory Disease Vaccine Market
12.1 Australia
12.2 China
12.3 India
12.4 Indonesia
12.5 Japan
12.6 Malaysia
12.7 Philippines
12.8 South Korea
12.9 Thailand
13 Competitive Scenario
13.1 Merger & Acquisition
13.2 Agreement, Collaboration, & Partnership
13.3 New Product Launch & Enhancement
13.4 Investment & Funding
13.5 Award, Recognition, & Expansion
14 Company Profiles
14.1 AstraZeneca
14.2 Bavarian Nordic
14.3 Bayer AG
14.4 Bio Farma
14.5 Dynavax Technologies Corporation
14.6 Emergent BioSolutions, Inc.
14.7 GlaxoSmithKline plc
14.8 Merck & Co., Inc.
14.9 Pfizer Inc.
14.10 Sanofi S.A.
14.11 Seqirus USA Inc.
For more information about this report visit https://www.researchandmarkets.com/r/dddddb
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
